EXUMA Biotech Adds H. Michael Shepard to Scientific Advisory Board and Steven R. Frank to Board of Directors

WEST PALM BEACH, Fla., June 16, 2020 /PRNewswire/ -- EXUMA Biotech Corporation, a clinical-stage biotechnology company discovering and developing CAR-T products and delivery solutions for liquid and solid tumors, is pleased to announce that H. Michael Shepard, Ph.D., an acting advisor to the company's HER2 program, has been appointed to the Scientific Advisory Board. Additionally, Steven R. Frank has been named to the company's Board of Directors effective April 2020. 

H. Michael Shepard, Ph.D. is known for leading the research team that discovered the antibody therapy Herceptin (trastuzumab). For this work, in 2019, Dr. Shepard and two other scientists were awarded the Lasker–DeBakery Clinical Medical Research Award, and in 2006, Dr. Shepard and his research team were awarded Harvard Medical School's Alpert Prize.

"I speak for the entire EXUMA Biotech team in expressing our enthusiasm in welcoming a long-time colleague and scientific trailblazer to our Scientific Advisory Board. Mike's contribution to cancer research and life-saving treatments are numerous, profound, and have ultimately changed our ability to understand and treat disease," said Gregory Frost, Ph.D., Chairman and CEO of EXUMA Biotech Corp.

EXUMA Biotech Corp. is also pleased to officially welcome Steven R. Frank to the Board of Directors. Mr. Frank currently serves as Global Chairman Investment Banking, Healthcare at JP Morgan. He joined JP Morgan in 2008 from Bear Stearns.

"Steve is an exemplary leader in the healthcare banking industry. His executive experience brings considerable value as we prepare for milestones supporting our two cellular therapy platforms: rPOC and logic-gated CAR-T," said Dr. Frost.

About EXUMA Biotech Corporation
EXUMA Biotech Corp. is a private Delaware corporation formed in November 2015 with operations in West Palm Beach, Florida, the Cayman Islands and Shanghai, China. EXUMA leverages its globally integrated science, development and informatics teams located across multiple time zones to accelerate the design, high-throughput screening, discovery and development of chimeric antigen receptor T cell (CAR-T) candidates for both solid and liquid tumor malignancies. The company is developing logic gated CAR-T platforms to advance TME-restricted cellular therapies for solid tumors, platforms that will allow for same day, rapid point of care (rPOC) administration for solid or liquid tumors, and highly scalable systems for global therapy deployment, beginning in Asia. Learn more at exumabio.com.

SOURCE EXUMA Biotech Corp.

Related Links

http://www.exumabio.com